TABLE 2.
Univariate analyses of variables associated with MACE in the training cohorts.
| Variables | Training group (n = 484) | MACE (n = 181) | No MACE (n = 303) | P-value |
| Age(yrs) | 67.54 ± 15.96 | 66.68 ± 15.67 | 68.05 ± 16.13 | 0.361 |
| Sex(n,%) | 0.799 | |||
| Male | 279(57.6%) | 103(56.9%) | 176(58.1%) | |
| Female | 205(42.4%) | 78(43.1%) | 127(41.9%) | |
| Hypertension(n,%) | 0.542 | |||
| YES | 318(65.7%) | 122(67.4%) | 196(64.7%) | |
| NO | 166(34.3%) | 59(32.6%) | 107(35.3%) | |
| Diabetes(n,%) | <0.001 | |||
| YES | 284(58.7%) | 130(71.8%) | 154(50.8%) | |
| NO | 200(41.3%) | 51(28.2%) | 149(49.2%) | |
| Smoking(n,%) | 0.002 | |||
| YES | 239(49.4%) | 106(58.6%) | 133(43.9%) | |
| NO | 245(50.6%) | 75(41.4%) | 170(56.1%) | |
| HF(n,%) | <0.001 | |||
| First | 218(45.0%) | 102(56.4%) | 116(38.3%) | |
| Former | 266(55.0%) | 79(43.6%) | 187(61.7%) | |
| CKD(n,%) | 0.723 | |||
| YES | 308(63.6%) | 117(64.6%) | 191(63.0%) | |
| NO | 176(36.4%) | 64(35.6%) | 112(37.0%) | |
| AF(n,%) | 0.788 | |||
| YES | 359(74.2%) | 133(73.5%) | 226(74.6%) | |
| NO | 125(25.8%) | 48(26.5%) | 77(25.4%) | |
| NYHA(n,%) | <0.001 | |||
| ≥3 Level | 237(49.0%) | 117(64.6%) | 120(39.6%) | |
| <3 Level | 247(51.0%) | 64(35.4%) | 183(60.4%) | |
| Medication care | ||||
| Diuretic(n,%) | 0.805 | |||
| YES | 365(75.6%) | 138(76.2%) | 228(75.2%) | |
| NO | 118(24.4%) | 43(23.8%) | 75(24.8%) | |
| Beta-blocker(n,%) | 0.919 | |||
| YES | 135(27.9%) | 50(27.6%) | 85(28.1%) | |
| NO | 349(72.1%) | 131(72.4%) | 218(71.9%) | |
| Statin(n,%) | 0.754 | |||
| YES | 143(29.5%) | 55(30.4%) | 88(29.0%) | |
| NO | 341(70.5%) | 126(69.6%) | 215(71.0%) | |
| MRA(n,%) | 0.312 | |||
| YES | 129(26.7%) | 53(29.3%) | 76(25.1%) | |
| NO | 355(73.3%) | 128(70.7%) | 227(74.9%) | |
| ARNI(n,%) | 0.522 | |||
| YES | 142(29.3%) | 50(27.5%) | 92(30.4%) | |
| NO | 342(70.7%) | 131(72.4%) | 211(69.6%) | |
| CCB(n,%) | 0.551 | |||
| YES | 155(32.0%) | 55(30.4%) | 100(33.0%) | |
| NO | 329(68.0%) | 126(69.6%) | 203(67.0%) | |
| ACEI(n,%) | 0.853 | |||
| YES | 142(29.3%) | 54(29.8%) | 88(29.0%) | |
| NO | 342(70.7%) | 127(70.2%) | 215(71.0%) | |
| ARB(n,%) | 0.309 | |||
| YES | 116(24.0%) | 48(26.5%) | 68(22.4%) | |
| NO | 368(76.0%) | 133(73.5%) | 235(77.6%) | |
| Clinical findings | ||||
| SBP(mm Hg) | 143.93 ± 17.85 | 144.37 ± 15.20 | 143.67 ± 19.29 | 0.660 |
| DBP(mm Hg) | 83.13 ± 12.81 | 84.04 ± 11.41 | 82.59 ± 13.57 | 0.208 |
| Lp-PLA2(ng/L) | 184.19 ± 35.31 | 206.34 ± 35.51 | 170.96 ± 27.79 | <0.001 |
| Hcy(umol/L) | 14.66 ± 5.57 | 16.81 ± 5.59 | 13.38 ± 5.16 | <0.001 |
| CK-MB(ug/L) | 45.81 ± 73.94 | 52.11 ± 105.95 | 42.06 ± 44.90 | 0.148 |
| TnT(ug/L) | 0.32 ± 1.00 | 0.27 ± 0.34 | 0.34 ± 1.23 | 0.477 |
| NT-proBNP(ng/L) | 1096.50 ± 1364.31 | 1481.60 ± 1613.94 | 866.46 ± 1132.45 | <0.001 |
| D-Dimer(ug/ml) | 1.66 ± 1.80 | 1.89 ± 1.2.08 | 1.53 ± 1.59 | 0.063 |
| Total cholesterol(mg/dl) | 194.46 ± 42.14 | 193.30 ± 40.59 | 195.23 ± 42.91 | 0.633 |
| LDL-C(mg/dl) | 111.34 ± 32.09 | 110.95 ± 28.99 | 111.34 ± 34.02 | 0.844 |
| HDL-C(mg/dl) | 54.51 ± 14.30 | 52.96 ± 13.53 | 55.67 ± 15.08 | 0.034 |
| Triglycerides(mg/dl) | 139.10 ± 102.78 | 148.84 ± 118.72 | 132.90 ± 90.37 | 0.109 |
| FDP(ug/L) | 12.94 ± 13.41 | 11.60 ± 11.31 | 13.73 ± 14.91 | 0.065 |
| Scr(umol/L) | 211.21 ± 253.42 | 206.89 ± 229.67 | 213.79 ± 266.93 | 0.772 |
| Uric Acid(umol/L) | 471.31 ± 194.77 | 493.12 ± 172.47 | 458.28 ± 206.13 | 0.047 |
| FPG(mmol/L) | 8.51 ± 6.09 | 9.02 ± 8.56 | 8.20 ± 3.92 | 0.154 |
| CRP(mg/L) | 43.85 ± 53.44 | 38.00 ± 51.82 | 47.34 ± 54.02 | 0.060 |
| WBC(103/μl) | 9.09 ± 4.47 | 8.40 ± 4.11 | 9.50 ± 4.63 | 0.009 |
| NEUT(103/μl) | 3.67 ± 2.04 | 3.67 ± 2.09 | 3.67 ± 2.01 | 0.795 |
| LYM(103/μl) | 1.26 ± 0.93 | 1.29 ± 0.77 | 1.25 ± 1.01 | 0.983 |
| NLR(%) | 4.36 ± 4.01 | 4.08 ± 3.64 | 4.53 ± 4.20 | 0.588 |
| HGB(g/L) | 106.41 ± 31.49 | 109.50 ± 31.30 | 104.57 ± 31.52 | 0.095 |
| PLT(103/μl) | 206.39 ± 89.96 | 207.43 ± 83.69 | 205.77 ± 93.64 | 0.845 |
HF, heart failure history; CKD, chronic kidney disease history; AF, atrial fibrillation history; NYHA, New York heart association; MRA, mineralocorticoid receptor antagonists; ARNI, angiotensin receptor enkephalinase inhibitors; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; SBP, systolic blood pressure; DBP, diastolic blood pressure; Lp-PLA2, lipoprotein associated phospholipase A2; Hcy, homocysteine; CK-MB, creatine kinase isoenzyme-MB; TnT, troponin T; NT-proBNP, N terminal pro B type natriuretic peptide; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FDP, fibrinogen degradation product; Scr, serum creatinine; FPG, fasting plasma glucose; CRP, C-reactive protein; WBC, white blood count; NEUT, neutrophil count; LYM, Lymphocyte count; NLR, neutrophil to lymphocyte ratio; HGB, hemoglobin; PLT, platelet count; P-value means difference between MACE group and No MACE group.